Please login to the form below

Not currently logged in

Merck Serono/ Domain Parkinson's deal

Merck Serono and Domain Therapeutics are to partner in a deal to develop drugs to target neurodegenerative diseases such as Parkinson's

Merck Serono - Merck's biopharmaceutical division - and Domain Therapeutics are to partner in a deal to develop drugs to target neurodegenerative diseases such as Parkinson's disease.

The agreement will see France-based biopharmaceutical company, Domain, offer Merck access to a portfolio of optimised investigational compounds. In return, Domain will receive €2m in an upfront payment, with up to €132m available in milestone payments for the first two products to be developed.

The compounds to be developed are positive allosteric modulators for metabotropic glutamate receptor 4 (mGluR4). Glutamate receptors are a member of the G-protein coupled receptor (GPCR) family, a group of proteins which transmit signals into cells, and are seen as therapeutic targets for Parkinson's disease.

"We are pleased to have the opportunity to work with Domain Therapeutics, which has developed great expertise in the GPCR area," said Bernhard Kirschbaum, executive vice president for global research and development at Merck Serono. "This partnership with Domain Therapeutics reflects our long-term commitment to develop new treatments for neurodegenerative diseases."

Pascal Neuville, CEO, Domain Therapeutics, said: "This agreement is a validation of Domain Therapeutics' business model of addressing difficult GPCRs and partnering compounds, with a significant deal, at an early stage of development."

17th January 2011


Featured jobs

Subscribe to our email news alerts


Add my company

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...
World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...